Cargando…

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide. Despite recent improvements in treatment and prevention, most of the current therapeutic options are weighted by side effects impacting patients’ quality of life. Better patient selection towards systemic treatments r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mauri, Gianluca, Vitiello, Pietro Paolo, Sogari, Alberto, Crisafulli, Giovanni, Sartore-Bianchi, Andrea, Marsoni, Silvia, Siena, Salvatore, Bardelli, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346106/ https://www.ncbi.nlm.nih.gov/pubmed/35264786 http://dx.doi.org/10.1038/s41416-022-01769-8

Ejemplares similares

Early‐onset colorectal cancer in young individuals
por: Mauri, Gianluca, et al.
Publicado: (2018)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
por: Giannini, Valentina, et al.
Publicado: (2022)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
por: Durinikova, Erika, et al.
Publicado: (2022)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
por: Russo, Mariangela, et al.
Publicado: (2022)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
por: Rizzetto, Francesco, et al.
Publicado: (2020)

Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2021)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Exploring the links between cancer and placenta development
por: Costanzo, Vincenzo, et al.
Publicado: (2018)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2018)

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer
por: Zhou, Hui, et al.
Publicado: (2022)

Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
por: Lastraioli, Elena, et al.
Publicado: (2023)

Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions
por: Picco, Gabriele, et al.
Publicado: (2017)

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview
por: Vacante, Marco, et al.
Publicado: (2020)

Perspectives of the Application of Liquid Biopsy in Colorectal Cancer
por: Ding, Yuhan, et al.
Publicado: (2020)

Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer
por: Rodriguez-Casanova, Aitor, et al.
Publicado: (2021)

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring
por: Martins, Ivana, et al.
Publicado: (2021)

Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis
por: Ulivi, Paola, et al.
Publicado: (2022)

Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions
por: Gattuso, Giuseppe, et al.
Publicado: (2022)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8edjntognmao44i873oi0cojqu